Synthetic growth-hormone secretagogue receptor agonist
PRODUCT PROFILE
GHRP-2
£44.00
GHRP-2 is synthetic growth-hormone secretagogue receptor agonist. Researchers examine it in relation to acute gh secretion, ghrelin-pathway pharmacology and pituitary testing.
Why it is distinct
Typically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordOpen COA
- DispatchConfirmed at checkout
Out of stock
Ask about availabilitySUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Preclinical
BPC-157
£32.99Batch COA availableBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Preclinical
TB-500
£32.99Batch COA availableTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
GHRP-2 is synthetic growth-hormone secretagogue receptor agonist. Researchers examine it in relation to acute gh secretion, ghrelin-pathway pharmacology and pituitary testing.
Research focus+
Researchers study its ability to cause a short rise in growth hormone and its wider effects on pituitary signalling. It is mainly a research tool rather than an authorised treatment.
How the mechanism differs+
Activates GHSR-1a and can influence GH plus other neuroendocrine signals depending on exposure.
Evidence and limitations+
Human challenge and diagnostic studies exist, but it has no broadly established therapeutic indication.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers study its ability to cause a short rise in growth hormone and its wider effects on pituitary signalling. It is mainly a research tool rather than an authorised treatment.
Activates GHSR-1a and can influence GH plus other neuroendocrine signals depending on exposure.
Typically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
Human challenge and diagnostic studies exist, but it has no broadly established therapeutic indication.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch COA availableShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch COA availableClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Experimental
PEG-MGF
£61.002 mgBatch COA availableA modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
UnavailableAsk about availability -
Experimental
IGF-1 LR3
£47.991 mgBatch COA availableDesigned for longer, less binding-protein-restricted IGF signalling than native IGF-1 or IGF-1 DES.
Available · 10 in stockAdd to basket